Ilya Pharma will present company updates at BioFuture hosted live in NYC 7-8 November and virtually 14-16 November
Conference topic is to - Reimagine the future of therapeutics
Bioprocessing and analytics industry business expert to spearhead major growth drive
Dr Andreas Fasth, Head of Clinical Developments and Medical Affairs at Ilya Pharma is on site and presenting "Accelerated wound healing by on-site production and delivery of CXCL12 by transformed lactic acid bacteria in 36 healthy volunteers with experimentally induced wounds".
Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.
The 2022 BIO International Convention will feature 100+ interactive sessions across 4 days covering a variety of therapeutic areas, business development, digital health, patient advocacy, public policy, and next-generation biotherapeutics, and the latest updates from industry experts on COVID-19 and the vaccine.
FDA clearance of IND for first-in-class ILP100-Topical immunotherapy treatment of surgical wounds in patients with prediabetes, diabetes and obesity
Ilya Pharma has made a strategic investment in its supply chain to facilitate development of its ILP pipeline by acquiring one of its long-term partners, Nordic Bioanalysis.
Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors